Correlations of hormone receptors (ER and PR), Her2/neu and p53 expression in breast ductal carcinoma among yemeni women

Open Cancer Immunology Journal

Volumn 4, Issue , 2011, Pages 1-9

  Ahmed, Hussain Gadelkarim ^a,b   Al Adhraei, Mohammed Ali ^c   Al Thobhani, Abdullah Kasim ^d  

^a Department of Histopathology and Cytology ^*  (Yemen)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c National Oncology Center   (Yemen)

^d SANA A UNIVERSITY   (Yemen)

Author keywords

Breast carcinoma; ER; Her2 neu and p53; PR; Yemeni

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; YEMEN;

EID: 84855490778     PISSN: None     EISSN: 18764010     Source Type: Journal    
DOI: 10.2174/1876401001104010001     Document Type: Article

References (60)

1. National Oncology Center: annual reports 2005-2007, Al-Jumhory Teaching Hospital, Sana'a, Yemen 2008.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14: 370-8.
4. Mario CS, José LP, Ricardo FS, Cláudio GZ. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?. Appl Immunohistochem Mol Morphol 2010; 18: 51-4.
5. Tang P, Hajdu SI, Lyman GH. Ductal carcinoma in situ: a review ofrecent advances. Curr Opin Obstet Gynecol 2007; 19: 63-7.
6. Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 2007; 37: 127-34.
7. Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ERalpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci 2006; 36(2): 137-43.
8. Pedrini JL, Pedrini M, Savaris RF, et al. Reassessing tumor markers in local recurrences of breast cancer: a new insight. Med Sci Monit 2004; 10: BR462-BR67.
9. Croce MV, Isla-Larrain M, Remes-Lenicov F, et al. MUC1cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol 2006; 21: 849-55.
10. Ferrero-Pous M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 2001; 9: 267-75.
11. Pinto AE, Andre S, Laranjeira C, et al. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 2005; 37: 45-50.
12. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep test in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol 1999; 17: 1983-7.
13. Pfister C, Moore L, Allard P, et al. Predictive value of cell cyclemarkers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999; 5: 4079-84.
14. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008; 110: 183-8.
15. Sughayer MA, Al-khawaja MM, Massarweh S, Al-masri M. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res 2006; 12(2): 83-6.
16. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13(1): 7-26.
17. Harris L, Fritsche H, Mennel R, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
18. Schorr MC, Pedrini JL, Savaris RF, Zettler CG. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?. Appl Immunohistochem Mol Morphol 2010; 18: 51-4.
19. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006; 66: 5278-86.
20. Schorr MC, Pedrini JL, Savaris RF, Zettler CG. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?. Appl Immunohistochem Mol Morphol 2010; 18(1): 51-4.
21. Hoque A, Menter DG, Sahin AA, et al. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 153-4.
22. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomark & Prevent 2002; 11: 601-7.
23. Amend K, Hicks D, Ambrosone CB. Breast cancer in African- American women: differences in tumor biology from European- American women. Cancer Res 2006; 66(17): 8327-30.
24. Telli ML, Kurian AW, Chang ET, Keegan TH, Ford JM, Gomez SL. Asian race and breast cancer subtypes: a study from the California Cancer Registry. J Clin Oncol 2008; 26: S 618.
25. Stierer M, Rosen H, Weber R, Hanns H, Jurgen S, Heinz T. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer correlation of histopathology and prognostic factors. Ann Surg 1993; 218(1): 13-21.
26. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. JCO 2003; 21(1): 28-34.
27. Hedayati-Moghadam MR. Correlation of HER2/neu overexpression, p53 protien accumulation and steroid receptor status with tumor characteristics: an Iranian study of breast cancer patients. Iranian J Publ Health 2008; 37(3): 19-28.
28. Mudduwa LKB. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters. Ind J Path Microbiol 2009; 52(2): 159-63.
29. Ayadi L, Khabir A, Amouri H, et al. Correlation of HER2 overexpression with clinicopathological parameters in Tunisian breast carcinoma. World J Surgical Oncol 2008; 6: 112.
30. Rashed MM, Ragab NM, Galal MK. The association of HER2/neu over-expression in relation to p53 nuclear accumulation, hormonal receptor status and common clinicopathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. Eur J Gen Med 2007; 4(2): 73-9.
31. Yarney J, Vanderpuye V, Clegg JN. Hormone receptor and HER2 expression in breast cancers among Sub-Saharan African women. Breast J 2008; 14(5): 510-11.
32. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR & HER-2/neu(C-erb B2) reactive pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pacific J Cancer Prev 2008; 9: 553-6.
33. Ahmed HG, Safi SH, Shumo AI, Abdulrazig M. Expression of estrogen and progesterone receptors among sudanese women with breast cancer: immunohistochemical study. Sudan J Medical Stud 2007; 2 (1): 5-6.
34. Almasri NM, Al-Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005; 7(5): R598-R604.
35. Al-Moundhri M, Nirmala V, AL-Mawaly K, et al. Significance of p53, Bcl-2, and HER2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003; 9(4): 181-276.
36. Lu X, Gu Y, Ding Y, et al. Correlation of ER, PR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Breast J 2008; 14 (3): 308-10.
37. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008; 110: 183-8.
38. Cho EY, Choi YL, Han JA, Kim KM, Oh YL. Expression and amplification of HER2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization. Pathol Inte 2008; 58: 17-25.
39. Chae BJ, Bae JS, Lee A, et al. P53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009; 39(4): 217-24.
40. Tammim L, Baker H, Sinowatz F. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Anticancer Res 2001; 21(1B): 743-8.
41. Ihemelandu CU, Dewitty RL, Leffall LD, Suryanarayana SM, Frederick WA. Clinical significance ofp53 and bcl-2 protein coexpression phenotypes in molecular breast cancer subtypes of premenopausal and post-menopausal African-American women. Am Surg 2009; 75(9): 777-84.
42. Olivotto IA, Truong PT, Speers CH, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 2004; 22; (9): 1769-70.
43. Colomer R, Beltran M, Dorcas J. It is not time to stop progesterone receptor testing in breast cancer. JCO 2005; 23(16): 3868-9.
44. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight Racial/ Ethnic Groups. Cancer 2001; 92(1): 37-45.
45. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15): 4429-34.
46. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15(4): 303-8.
47. Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural appalachian population. Cancer Epidemiol Biomarkers Prev 2008; 17(12): 3319-24.
48. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triplenegative tumors in an urban cancer center. Cancer 2008; 113(3): 608-15.
49. Stead LA, Lash TL, Sobieraj JE, et al. Triple negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
50. Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristic and HER2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58: 611-6.a
51. Ratnatunga N, Liyanapathirana LVC. Hormone receptor expression and HER/2 amplification in breast carcinoma in a cohort of Sri- Lankans. Papers 2007; 52(4): 133-6.
52. Anim JT, John B, AbdulSathar SA, et al. Relationship between the expression of various markers and prognostic factors in breast cancer. Acta histochemica 2005; 107: 87-93.
53. Ferrero JM, Ramaioli A, Formento JL, et al. P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol 2000; 11: 393-7.
54. Climent MA, Segui MA, Peiro G, et al. Prognostic value of HER2/neu and p53 expression in node positive breast cancer. HER2/neu effect on adjuvant tamoxifen treatment. Breast J 2001; 10: 67-77.
55. Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian SAA, Eftekhar- Zadeh MashhadiI, Hedayati-Moghadam MR. Correlation of HER2/neu over-expression, p53 protein accumulation and steroid receptor status with tumor characteristics: an Iranian study of breast cancer patients. Iranian J Publ Health 2008; 37(3): 19-28.
56. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17: 1545-54.
57. Yamashita H, Toyama T, Nishio M, et al. P53 protein accumulation predicts resistance to endocrine therapy and decreased post relapse survival in metastatic breast cancer. Breast Cancer Res 2006; 8(4): R 48.
58. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005; 11(6): 433-9.
59. Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER 2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad 2008; 20(3): 23-6.
60. Hussein MR, Srah A, Abdulwahed AR. Alteration of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int 2008; 32: 698-707.